Real estate
Autolus Therapeutics, based in London, UK, announced plans to locate its U.S. headquarters in Rockville, Maryland. In addition to the headquarters, it will have all U.S.-based research and development, commercial and corporate functions and a first full commercial-scale manufacturing center at the location.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
The white-hot biotech hub of Kendall Square just got a little bit more crowded. Ireland-based Allergan plc announced this morning that the company will establish an R&D facility in the Cambridge, Mass. neighborhood.
- Jason Marks appointed Chief Legal Officer / General Counsel
Recipharm today announces that it will initiate a process to explore the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK.
Paris-based Sanofi signed the lease on two buildings yet to be built in East Cambridge, Massachusetts. Sanofi is the state’s largest life science employer and plans to shift 2,700 staffers into the two buildings at Cambridge Crossing.
Cambridge provides member companies with a unique, full-service platform featuring highly flexible, cost-effective, move‑in‑ready and well-equipped wet laboratory and office space; strategic programming and mentoring; and access to seed capital through the Alexandria Seed Capital Platform
Orchard Therapeutics is expanding its physical footprint in California. The U.K.-based company signed a long-term lease to build out a gene therapy manufacturing facility in Fremont, Calif. The 150,000-square-foot facility will add to the company’s presence in the Bay Area.
Pfizer’s La Jolla cancer research center is set to grow by about 100 people. The pharma giant is transferring employees from a recently shuttered South San Francisco immunology site to bolster the work conducted near San Diego.
At its San Diego site, the company plans to establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D, which will also include Phase I GMP manufacturing.
PRESS RELEASES